IL22 and colorectal cancer: Turicibacter, which is enriched in murine colorectal cancer (60), promotes pro-inflammatory effects, while IL-22 treatment, which boosts anti-inflammatory responses, significantly depletes Turicibacter, suggesting its involvement in inflammation (61).